PhD: Anti-viral Pathways in Vascular Dementia

Reading Time: 5 minutes
no comments   

Website UCL University College London

Closing date: 8th January

bluesky@ucl.ac.uk

 

UCL seeks a PhD student to investigate how interferon signalling in microglia damages the blood-brain barrier in vascular dementia, combining genetics, vascularised brain organoids and blood biomarkers, on a fully funded UCL/Birkbeck-MRC PhD with Dr Dervis Salih and Professor John Hardy.


  • Supervisors: Dr Dervis Salih, Prof John Hardy, Dr Daria Gavriouchkina, Dr Amanda Assoni
  • Funding: Competition Funded PhD Project – UCL/Birkbeck-MRC Co-funded studentships
  • Eligibility: Students Worldwide
  • Closing date: Friday 8th January 2027

About the Project

Vascular dementia (VaD) is the second most common form of dementia and has no disease-modifying treatment, while its burden rises with population ageing and the growing prevalence of hypertension, diabetes and stroke. Its principal pathology, cerebral small vessel disease (SVD), is characterised by blood-brain barrier (BBB) breakdown, white matter injury and chronic microglial activation. Yet the molecular pathways connecting microglial inflammation, including the response to common viral infections, to cerebrovascular dysfunction and cognitive decline remain poorly defined. The supervisory group has established that interferon (IFN) signalling in microglia is a key axis of neurodegeneration risk: they identified interferon-stimulated genes (ISGs) such as OAS1 within Alzheimer’s disease (AD) risk loci, and position IFITM3 as a hub gene in the human AD IFN-responsive microglial network (Magusali et al., 2021). This is coupled together with an age-upregulated IFN-responsive microglial module in the ageing hippocampus (Graham et al., 2025). Critically, IFITM3 is expressed by both microglia and cerebrovascular endothelium, and its endothelial inhibition alleviates AD phenotypes in vivo (Feng et al., 2025), and SVD heritability is enriched across endothelial, mural and glial cells (Ziegler et al., 2026). Pilot data show that IFN-gamma and poly(I:C) reproducibly reshape the proteome of human iPSC-derived microglia.

Hypothesis. IFN signalling in microglia drives pathological crosstalk with cerebrovascular endothelium through coordinated ISG induction, with IFITM3 as a hub, causing BBB dysfunction and accelerating SVD. Genetic variation in this pathway modifies VaD risk, and systemic infection amplifies it through circulating IFN-driven factors.

Aim and objectives. The overarching aim is to investigate the IFN/ISG pathway as a causal mechanism and therapeutic axis in VaD that may be detected in blood biomarkers pursued through three objectives.

Objective 1 — Genetics. Identify IFN/ISG genetic variants associated with VaD and the neurovascular unit (NVU) cell types in which they act. This uses MAGMA gene-set analysis across MEGAVCID, stroke and coronary heart disease GWAS; a new GWAS of UK Biobank VaD cases (N=1,805); H-MAGMA/eMAGMA to map risk genes to NVU cell types; Mendelian randomisation; PheWAS; and AlphaGenome to predict regulatory impact and rank top ISG candidates.

Objective 2 — Functional causality. Determine which ISGs causally mediate BBB disruption. Using an established protocol for vascularised human brain organoids (assembloids) will be stimulated with IFN-gamma and poly(I:C), with RNAi knockdown of top candidates in microglia or endothelium, and testing of an IFITM3 inhibitor compound. Readouts include BBB integrity (FITC-dextran permeability, Angiopep-2 transcytosis, CLDN5/ZO-1/CD31 staining), microglial state (IBA1, TMEM119, CD68), FACS-sorted cell-type-specific RNA-seq, and LIANA ligand-receptor analysis.

Objective 3 — Biomarkers. Identify candidate blood biomarkers by profiling organoid secretomes (DIA mass spectrometry, LEGENDplex/ELISA) and plasma from a mouse stroke model, then testing hits against VaD status in UK Biobank Olink proteomics and integrating with the Objective 1 genetics.

Importance of expected results. The project will deliver the first systematic map of IFN/ISG genetic architecture in VaD, the first human model to dissect IFN-driven microglial-endothelial crosstalk causally, and a cross-validated panel of candidate blood biomarkers. Because pharmacological tools against IFITM3 already exist, the findings offer a direct route to therapeutic testing — addressing MRC priorities in neurodegeneration, dementia and inflammation, and combining quantitative/data-science approaches with human iPSC models that reduce reliance on animal work.

Supervisory team and training. The student will be based in the UK Dementia Research Institute and Department of Neurodegeneration at Queen Square Institute of Neurology. The team unites complementary expertise: Dr Dervis Salih (main supervisor; microglial IFN signalling, iPSC models, glial gene networks), Prof. John Hardy (pioneer of neurodegeneration genetics) and Dr Daria Gavriouchkina (single-cell and spatial transcriptomics). Collaborators extend the project across UCL and the UK DRI network — Dr Amanda Assoni and Dr Mootaz Salman (vascularised organoids), Prof. David Selwood and Prof. Greg Towers (IFITM small-molecule tools, immunology/virology), Dr Barry McColl (stroke studies), Dr Bethany Geary (mass spectrometry) and Prof. Valentina Escott-Price (statistical genetics).

Training is interdisciplinary and aligned with MRC-prioritised skills: quantitative methods (population genetics, Mendelian randomisation, PheWAS, RNA-seq and network analysis, deep-learning variant interpretation with AlphaGenome) and laboratory techniques (iPSC/organoid culture, FACS, lentiviral knockdown, immunocytochemistry, permeability assays, DIA proteomics, multiplex cytokine profiling). Support comes through weekly one-to-one and monthly team meetings, lab and journal clubs, the UK DRI bioinformatics community and UCL Doctoral School, with progress monitored by a thesis committee and UCL’s formal upgrade process, and dissemination through national and international conferences.

Funding Notes

Fully funded place including home (UK) tuition fees and a tax-free annual stipend in the region of £ 23,805

References

  • Feng Y, Wang S, Yang D, Zheng W, Xia H, Zhu Q, Wang Z, Hu B, Jiang X, Qin X, Ni C, Pan W, Zhao Y, Pan S, Zhang Y, Song W. Inhibition of IFITM3 in cerebrovascular endothelium alleviates Alzheimer’s-related phenotypes. Alzheimers Dement. 2025 Feb;21(2):e14543. doi: 10.1002/alz.14543. Epub 2025 Jan 14. PMID: 39807629; PMCID: PMC11851164.
  • Graham AC, Bellou E, Harwood JC, Yaman U, Celikag M, Magusali N, Rambarack N, Botia JA, Sala Frigerio C, Hardy J, Escott-Price V, Salih DA. Human longevity and Alzheimer’s disease variants act via microglia and oligodendrocyte gene networks. Brain. 2025 Mar 6;148(3):969-984. doi: 10.1093/brain/awae339. PMID: 39778705; PMCID: PMC11884759.
  • Magusali N, Graham AC, Piers TM, Panichnantakul P, Yaman U, Shoai M, Reynolds RH, Botia JA, Brookes KJ, Guetta-Baranes T, Bellou E, Bayram S, Sokolova D, Ryten M, Sala Frigerio C, Escott-Price V, Morgan K, Pocock JM, Hardy J, Salih DA. A genetic link between risk for Alzheimer’s disease and severe COVID-19 outcomes via the OAS1 gene. Brain. 2021 Dec 31;144(12):3727-3741. doi: 10.1093/brain/awab337. PMID: 34619763; PMCID: PMC8500089.
  • Ziegler KC, Askarova A, Gergian C, Yaa RM, van Dalen JD, Transfeld JL, Zoppi F, Du J, Clode D, Rahbar F, Graham RE, Sargurupremraj M, Debette S, Gonda DD, Levy ML, Chandran S, Falk S, Karow M, Matthews PM, Coufal NG, Nott A. The brain neurovascular epigenome and its association with dementia. Neuron. 2025 Oct 30:S0896-6273(25)00754-8. doi: 10.1016/j.neuron.2025.10.001. Epub ahead of print. PMID: 41173000.

To apply for this job please visit www.findaphd.com.